// App-Quantinova.ai

: Aurora Kinase B/C Inhibitor GSK1070916 Specifically Targets Juvenile Myelomonocytic Leukemia Cells with SHP2(PTPN11) Mutation

Researchers

Presenter

  • Chunxiao He

Principal Investigators

  • Dengyang Zhang

  • Yao Guo

  • Yuming Zhao

  • Junbin Huang

  • Hongman Xue

  • Chun Chen

  • Yun Chen

  • Zhizhuang Joe Zhao

Medical Centers

  • Sun Yat-Sen University, Shenzhen, China

  • Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Leukemia, juvenile myelomonocytic

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

Biomarkers

  • B-cell lymphoma-extra large

  • Aurora kinase A

  • Breakpoint Cluster Region

  • Peripheral blood mononuclear cell

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • Erythropoietin

  • GSK1070916

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved